Overview / Abstract: |
STATEMENT OF NEED Kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States (ACS, 2020). An estimated 73,750 new cases are reported annually and 14,830 people die of the disease. Renal cell carcinoma, which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Due to its often asymptomatic presentation, many patients have advanced disease at diagnosis, which is associated with poor outcomes. The 5-year survival rate for patients with regional RCC is only 70% and drops to a dismal 12% for those with distant metastases (ACS, 2020). TARGET AUDIENCE Oncology and urology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with RCC. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: 1.) Distinguish the mechanisms of action of IO agents and VEGFR TKIs in advanced RCC |
Expiration |
Nov 29, 2021 |
Discipline(s) |
Nurse Practitioner , Nursing CNE |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
1.0 NCPD, ILNA |
Accreditation |
ANCC |
Presenters / Authors / Faculty |
Laura S. Wood, RN, MSN, OCN® (Chairperson) Nazy Zomorodian, RNC, MSN, CUNP, CCRC Virginia Seery, CRNP, MSN Colleen Lewis, NP |
Activity Specialities / Related Topics |
Nephrology, Oncology / Cancer / Radiation Therapy, Urology |
Sponsors / Supporters / Grant Providers |
This activity is supported by a medical educational grant from Exelixis, Inc. and independent educational grants from Eisai and Merck. |
Keywords / Search Terms |
i3 Health oncology, RCC, renal cell carcinoma, kidney cancer, CNE, NCPD, free CNE, free NCPD, ILNA points, free ILNA points, i3 Health, CE, free CE Free CE CME |